Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)
Summary
This study aims to assess how glimepiride affects the recovery from hypoglycemia in participants with type 2 diabetes mellitus. The primary objective is to estimate the time taken by participants to recover from hypoglycemia to euglycemia after treatment with either 2 mg or 4 mg of glimepiride when compared to placebo.
Timeline
- Start
- 2012-07-18
- Primary completion
- 2013-01-09
- Completion
- 2013-01-23
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Placebo vs Glimepiride 4 mg; Mean Difference (Final Values) 35.33 (90% CI -2.08 to 72.74) NCT01614769 ↗
registry analysis (superiority or other test); Placebo vs Glimepiride 4 mg; Mean Difference (Final Values) -0.13 (90% CI -0.24 to -0.03) NCT01614769 ↗
registry analysis (superiority or other test); Placebo vs Glimepiride 4 mg; Mean Difference (Final Values) -7.27 (90% CI -13.30 to -1.24) NCT01614769 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glimepiride | Small molecule | 2 mg | — |
| Subject | Glimepiride | Small molecule | 4 mg | — |